|
FAST ATMP webinar part 3 - Market authorization, hospital exemptions, reimbursement
|
|
2
|
66
|
April 1, 2025
|
|
FAST ATMP webinar part 2 - Non-clinical development, clinical development, Regulation and legislation
|
|
2
|
72
|
April 1, 2025
|
|
FAST ATMP Webinar part 1 - Patient participation, classification of ATMPs, product development
|
|
2
|
138
|
April 1, 2025
|
|
Is there a guidance document for ATMPs during process changes or manufacturing scale-up?
|
|
1
|
54
|
March 19, 2025
|
|
Vaccines & the EU HTA Regulation: Why, What and How?
|
|
0
|
30
|
March 19, 2025
|
|
Is there a format or guidance document for writing a product development plan and IMPD specifically for ATMPs
|
|
3
|
55
|
March 14, 2025
|
|
DARE-NL Annual Consortium Meeting
|
|
0
|
28
|
March 14, 2025
|
|
P3Dx Symposium – De Toekomst van Testen (in Dutch)
|
|
0
|
21
|
March 13, 2025
|
|
7 recommendations to to improve reproducibility, comparability, and visibility in preclinical TRT research
|
|
0
|
40
|
March 13, 2025
|
|
Online information about Gene Therapy for monogenic diseases - for patients
|
|
0
|
40
|
March 11, 2025
|
|
How can the lack of formal documentation in patient involvement activities be addressed?
|
|
4
|
116
|
March 11, 2025
|
|
Pharmacy preparation vs hospital exemptions – is there a difference?
|
|
1
|
73
|
March 3, 2025
|
|
What are the differences in regulatory pathways for obtaining approval for repurposed drugs in the EU, UK and US?
|
|
0
|
32
|
February 25, 2025
|
|
For which infectious diseases are there Controlled Human Infection Models (CHIMs) available?
|
|
0
|
38
|
February 25, 2025
|
|
Webinar: “Clinical Trials in Focus: Innovations and Patient Perspectives in Rare Diseases”
|
|
0
|
22
|
February 24, 2025
|
|
When to use Human Challenge Models and Controlled Human Infection Models
|
|
0
|
21
|
February 19, 2025
|
|
Is the drug that I want to prescribe reimbursed?
|
|
1
|
56
|
February 18, 2025
|
|
Dutch ATMP summit
|
|
0
|
48
|
December 12, 2024
|
|
Is there a overview of tools, methods and database that can be used for Drug Repurposing?
|
|
3
|
63
|
February 17, 2025
|
|
iDR25 - Pre-Conference Workshops (Brussels)
|
|
1
|
55
|
February 17, 2025
|
|
Succesvolle voorbeelden van drug repurposing? / Examples of successful drug repurposing?
|
|
1
|
54
|
February 17, 2025
|
|
Funding opportunities for drug repurposing
|
|
5
|
140
|
February 17, 2025
|
|
CAT template examples
|
|
2
|
82
|
February 14, 2025
|
|
Exploring Academic ATMP Development: Insights from Belgium & Comparisons with the Netherlands
|
|
0
|
30
|
February 14, 2025
|
|
Patient recorded outcome measurements (PROMs) for rare diseases
|
|
1
|
41
|
February 13, 2025
|
|
Orphan Drug designation
|
|
2
|
65
|
February 6, 2025
|
|
EU HTA regulation impact and ATMP market access?
|
|
0
|
51
|
February 5, 2025
|
|
Patientregistries on rare disease
|
|
4
|
40
|
February 4, 2025
|
|
Difference Orphan designation and marketing authorisation
|
|
1
|
87
|
February 4, 2025
|
|
Current and Innovative Radionuclides for Medical Imaging and Therapy | PRISMAP School
|
|
0
|
22
|
January 31, 2025
|